A pituitary tumor is a complex whole-body disease that alters gene (genome), mRNA (transcriptome), protein (proteome), and metabolite (metabolome) levels, and that involves multiple factors, processes, and consequences. Individual variation is involved in each stage of prediction/prevention, early-stage diagnosis/therapy, and late-stage diagnosis/therapy. The development of “-omics” methods (genomics, transcriptomics, proteomics, and metabolomics) and systems biology has promoted change of paradigms from the traditional single-factor strategy to a multi-parameter systematic strategy. New integrative opinion has been brought in the model of predictive screening and prognostic assessment of pituitary tumor that previously only depended on changes of serum single-hormone change and pituitary imaging. The therapeutic model of cancer has changed from general radiotherapy and chemotherapy to a personalized strategy. The development of predictive, preventive, and personalized medicine is substantially changing the understanding, prediction, prevention, and therapeutic model of pituitary tumors from a systematic and comprehensive point of view. From the point of view of systematic strategies in pituitary tumors, it is necessary to systematically study changes in the genome, transcriptome, proteome, peptidome, and metabolome in pituitary tumor tissue and body-fluids (cerebrospinal fluid, CSF; serum/plasma). Systems biology strategies will be used to integrate all experimental data and all clinical information of an individual to propose the corresponding molecular networks specific to a pituitary tumor for efficient prediction screening, early-stage diagnosis, prognostic assessment, and individualized prevention and therapy. We welcome authors to submit review articles and original research reports to address the molecular mechanisms and biomarkers of pituitary tumors at the levels of the genome, transcriptome, proteome, metabolome, interactome, and integrative systems biology in this series. Potential topics include, but are not limited to,: (1) developing and testing novel biomarker of functional pituitary tumors, (2) heterogeneity of nonfunctional pituitary adenomas, (3) molecular mechanism and biomarkers of non-functional pituitary adenomas, (4) molecular mechanism and biomarker of pituitary tumor invasion, (5) tumor angiogenesis in pituitary adenomas, (6) oxidative stress in pituitary adenomas, (7) protein post-translational modifications and isoforms in pituitary adenomas, and (8) cell and animal model studies in pituitary tumors.
A pituitary tumor is a complex whole-body disease that alters gene (genome), mRNA (transcriptome), protein (proteome), and metabolite (metabolome) levels, and that involves multiple factors, processes, and consequences. Individual variation is involved in each stage of prediction/prevention, early-stage diagnosis/therapy, and late-stage diagnosis/therapy. The development of “-omics” methods (genomics, transcriptomics, proteomics, and metabolomics) and systems biology has promoted change of paradigms from the traditional single-factor strategy to a multi-parameter systematic strategy. New integrative opinion has been brought in the model of predictive screening and prognostic assessment of pituitary tumor that previously only depended on changes of serum single-hormone change and pituitary imaging. The therapeutic model of cancer has changed from general radiotherapy and chemotherapy to a personalized strategy. The development of predictive, preventive, and personalized medicine is substantially changing the understanding, prediction, prevention, and therapeutic model of pituitary tumors from a systematic and comprehensive point of view. From the point of view of systematic strategies in pituitary tumors, it is necessary to systematically study changes in the genome, transcriptome, proteome, peptidome, and metabolome in pituitary tumor tissue and body-fluids (cerebrospinal fluid, CSF; serum/plasma). Systems biology strategies will be used to integrate all experimental data and all clinical information of an individual to propose the corresponding molecular networks specific to a pituitary tumor for efficient prediction screening, early-stage diagnosis, prognostic assessment, and individualized prevention and therapy. We welcome authors to submit review articles and original research reports to address the molecular mechanisms and biomarkers of pituitary tumors at the levels of the genome, transcriptome, proteome, metabolome, interactome, and integrative systems biology in this series. Potential topics include, but are not limited to,: (1) developing and testing novel biomarker of functional pituitary tumors, (2) heterogeneity of nonfunctional pituitary adenomas, (3) molecular mechanism and biomarkers of non-functional pituitary adenomas, (4) molecular mechanism and biomarker of pituitary tumor invasion, (5) tumor angiogenesis in pituitary adenomas, (6) oxidative stress in pituitary adenomas, (7) protein post-translational modifications and isoforms in pituitary adenomas, and (8) cell and animal model studies in pituitary tumors.
